- Home
- EFT vs TNXP Comparison
EFT vs TNXP Comparison
Compare EFT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFT
- TNXP
- Stock Information
- Founded
- EFT 2004
- TNXP 2007
- Country
- EFT United States
- TNXP United States
- Employees
- EFT N/A
- TNXP N/A
- Industry
- EFT Finance Companies
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- EFT Finance
- TNXP Health Care
- Exchange
- EFT Nasdaq
- TNXP Nasdaq
- Market Cap
- EFT 327.7M
- TNXP 335.6M
- IPO Year
- EFT N/A
- TNXP N/A
- Fundamental
- Price
- EFT $12.09
- TNXP $37.98
- Analyst Decision
- EFT
- TNXP Buy
- Analyst Count
- EFT 0
- TNXP 1
- Target Price
- EFT N/A
- TNXP $70.00
- AVG Volume (30 Days)
- EFT 100.8K
- TNXP 2.2M
- Earning Date
- EFT 01-01-0001
- TNXP 08-11-2025
- Dividend Yield
- EFT 10.63%
- TNXP N/A
- EPS Growth
- EFT N/A
- TNXP N/A
- EPS
- EFT 1.73
- TNXP N/A
- Revenue
- EFT N/A
- TNXP $9,831,000.00
- Revenue This Year
- EFT N/A
- TNXP $22.87
- Revenue Next Year
- EFT N/A
- TNXP $711.66
- P/E Ratio
- EFT $7.62
- TNXP N/A
- Revenue Growth
- EFT N/A
- TNXP N/A
- 52 Week Low
- EFT $11.10
- TNXP $6.76
- 52 Week High
- EFT $13.44
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- EFT 39.24
- TNXP 43.12
- Support Level
- EFT $12.00
- TNXP $34.50
- Resistance Level
- EFT $12.24
- TNXP $53.55
- Average True Range (ATR)
- EFT 0.09
- TNXP 6.41
- MACD
- EFT -0.01
- TNXP -1.97
- Stochastic Oscillator
- EFT 32.69
- TNXP 11.06
About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest
Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.